Amgen Inc. (AMGN) shares closed near an all-time high of $432.42 on August 28, trading above the consensus analyst price target after a strong Q2 report. The company reported quarterly revenue of $10.05 billion, marking the first time it crossed the $10 billion threshold, with adjusted earnings of $6.29 beating estimates by nearly 12%. Management raised full-year guidance for both revenue and earnings, driven by a portfolio where six growth drivers now supply close to 70% of product sales.
The stock's valuation has expanded significantly, trading at approximately 18.4x forward earnings, which is near the high end of its recent range and above key peers like AbbVie and Biogen. While the company benefits from a robust pipeline including Repatha, EVENITY, and TEZSPIRE, the market has largely priced in these growth drivers. Analysts note that with low-single-digit revenue growth modeled for the future, the stock offers limited cushion against potential setbacks or slower-than-expected legacy franchise declines.
Key risks include competition from Merck's newly approved oral PCSK9 inhibitor, Enlicitide, which targets Amgen's largest product, Repatha. Although Amgen's Chief Commercial Officer argues the new drug has different labeling and food restrictions, the approval introduces a variable that could pressure Repatha's market share. Additionally, the company disclosed a cybersecurity incident involving the exfiltration of patient health information from third-party cloud storage, though it stated this would not materially impact its financial condition.
Looking ahead, TIKR's valuation model projects Amgen at around $495 by 2030, implying a low-single-digit annual return plus a dividend yield near 2.3%. The upcoming November 2 earnings report will be critical to test whether the six growth drivers can continue to outpace legacy declines and if Repatha can maintain its share against new competition. At current prices, the margin of safety is considered gone, requiring flawless execution to justify the premium valuation.
📈 AMGN shares hit $432.42 all-time high after 51% annual gain.
💰 Q2 revenue crossed $10B with adjusted earnings beating consensus by 12%.
🚀 Management raised full-year guidance driven by six growth drivers.
⚠️ Merck's new drug poses competitive risk to AMGN's Repatha franchise.
🔒 Cyber incident exfiltrated patient data but expects no material financial impact.
📈 AMGN shares closed at $432.42 near an all-time high, trading above the $388 average analyst price target after a 51% gain over the past year.
💰 Q2 revenue reached $10.05 billion, crossing the $10 billion mark for the first time, with adjusted earnings of $6.29 beating consensus by nearly 12%.
🚀 Management raised full-year guidance for both revenue and earnings, driven by six growth drivers that now account for roughly 70% of product sales.
📊 The stock trades at 18.4x forward earnings, a premium valuation near the high end of its recent range compared to peers like AbbVie (16.8x) and Biogen (16.5x).
💉 Repatha revenue rose 37% to $953 million, while EVENITY grew 38% and TEZSPIRE increased 42%, diversifying the portfolio away from biosimilar erosion.
⚠️ Merck received FDA approval for Enlicitide, an oral PCSK9 inhibitor that directly targets Repatha, introducing a competitive risk to Amgen's largest franchise.
🔒 AMGN disclosed a cybersecurity incident where patient health data was exfiltrated from third-party cloud storage, though the company expects no material financial impact.
📉 TIKR's model projects a base case return of roughly 14% total by 2030, or about 3% annually, plus a dividend yield near 2.3%.
🔮 The upcoming November 2 earnings report will be a critical test for whether growth drivers can outpace legacy declines and defend market share.
📉 Analyst sentiment is mixed with 16 Hold ratings against 10 Buy/Outperform, and the average price target remains below the current market price.
Bullish Signals
Q2 revenue hit $10.05B with adjusted earnings of $6.29.
Management raised full-year guidance for revenue and earnings.
Growth drivers now supply close to 70% of sales.
Repatha revenue surged 37% to $953 million.
UPLIZNA grew 90% across three approved indications.
Risk Factors
Trades at 18.4x forward earnings above $388 consensus target.
Merck's Enlicitide threatens Repatha, Amgen's largest product.
Cyber incident exposed patient data from third-party cloud storage.
Legacy franchises decline, constraining revenue to low-single-digit growth.
Analysts cautious with 16 Holds vs 10 Buys.
Bullish Signals
Amgen reported Q2 revenue of $10.05 billion, crossing the $10 billion threshold for the first time with adjusted earnings of $6.29 beating consensus by nearly 12%.
Management raised full-year guidance for both revenue and earnings, signaling confidence in the company's growth trajectory despite high valuations.
The portfolio mix has improved significantly as six growth drivers now supply close to 70% of product sales, reducing reliance on the denosumab franchise.
Repatha revenue surged 37% to $953 million, driven by expanding use in primary prevention among high-risk patients and increased prescribing per physician.
The Rare Disease portfolio is showing exceptional strength with UPLIZNA growing 90% across three approved indications.
Non-GAAP operating margins are holding near 45% to 46% as Horizon acquisition amortization rolls off, supporting strong profitability.
Risk Factors
The stock trades at 18.4x forward earnings, above the consensus analyst price target of $388, leaving little margin of safety for execution errors.
Merck's FDA approval of Enlicitide, an oral PCSK9 inhibitor, poses a direct competitive threat to Repatha, Amgen's largest single product.
The company disclosed a cybersecurity incident involving the exfiltration of patient health information and proprietary data from third-party cloud storage.
Legacy franchises including Prolia, XGEVA, and Enbrel are declining, which constrains overall revenue growth to low-single-digit projections.
Analyst sentiment is cautious with 16 Hold ratings versus only 10 Buy/Outperform, and the average price target remains below the current market price.
Wall Street analysts have issued fresh ratings on major biopharma stocks, with Jefferies initiating a Buy on Gilead Sciences and a Hold on Amgen, while JPMorgan maintained an Overweight rating on clinical-stage oncology firm Oric Pharmaceuticals. These moves reflect a nuanced market view where Gilead is seen as well-positioned for long-term cash generation, Amgen is viewed as fairly valued after a significant recent run-up, and Oric is considered undervalued following a competitor-driven stock dip.
Gilead reported strong Q4 2025 results with revenue of $7.93 billion, beating estimates, driven by growth in its flagship HIV therapies Biktarvy and Descovy. The company benefits from a clean intellectual property runway extending to 2036, allowing for predictable cash flow and shareholder returns. Conversely, Amgen delivered solid Q4 earnings but faces headwinds from biosimilar competition on key products like Prolia and XGEVA, as well as declining revenue in its Enbrel franchise.
Oric Pharmaceuticals, a clinical-stage oncology company with no current product revenue, saw shares drop 16% due to unrelated competitor news. Analysts view this pullback as unjustified given the differentiated data of its lead asset, rinzimetostat, which showed a high response rate in prostate cancer trials. The company holds substantial cash reserves providing a runway into late 2028, though it carries binary risk associated with upcoming Phase 3 trial readouts expected in 2026.
Analysts highlight specific financial metrics and risks for each ticker. Gilead trades at a forward P/E of 16x with a low beta of 0.37, offering a dividend yield of 2.2%. Amgen's stock trades above Jefferies' $350 price target, limiting near-term upside despite strong execution. Oric presents a high-risk, high-reward profile with a consensus analyst target significantly higher than its current price, contingent on successful clinical data readouts in the second half of 2026.
📈 Jefferies rates Gilead Buy with $180 target citing clean IP until 2036.
📉 Jefferies holds Amgen at $350 after 35% rally above that level.
💰 Gilead Q4 revenue hit $7.93B, beating the $7.85B consensus estimate.
🔬 Amgen Q4 revenue reached $9.87B with Repatha growth of +44%.
🧬 Oric lead asset shows 55% response rate in prostate cancer trials.
📈 Jefferies initiates coverage on Gilead Sciences (GILD) with a Buy rating and $180 price target, citing a clean IP runway until 2036 and high operating margins.
📉 Jefferies assigns a Hold rating to Amgen (AMGN) with a $350 price target, noting the stock has already rallied 35% and is trading above this level.
➕ JPMorgan maintains an Overweight rating on Oric Pharmaceuticals (ORIC) following a 16.07% share price drop driven by unrelated competitor news.
💰 Gilead reported Q4 2025 revenue of $7.93 billion, beating the $7.85 billion consensus estimate, with non-GAAP EPS of $1.86.
🔬 Amgen delivered Q4 revenue of $9.87 billion against a $9.66 billion estimate, with Repatha leading growth at +44%.
📉 Amgen's Enbrel revenue declined 48% to $532 million in Q4, signaling continued structural decline for the established franchise.
💊 Gilead's flagship HIV therapy Biktarvy generated $3.97 billion in Q4, up 5%, while Descovy surged 33% to $819 million.
🧬 Oric's lead asset rinzimetostat posted a 55% PSA50 response rate in metastatic castration-resistant prostate cancer trials.
💵 Oric holds $392.3 million in cash, projecting a funding runway into the second half of 2028.
📊 Gilead shares are up 19.46% year-to-date and trade at $146.63, implying upside from Jefferies' $180 target.
⚠️ Amgen faces real headwinds from accelerating biosimilar competition for Prolia and XGEVA.
🎯 Oric's consensus analyst target is $21.23 against a current price of $11.65, reflecting binary pipeline risk.
Bullish Signals
Clean IP runway with no major loss until 2036.
Gilead Q4 revenue $7.93B beat consensus of $7.85B.
Non-GAAP EPS $1.86 beat estimate of $1.85.
Descovy revenue surged 33% to $819 million in Q4.
Yeztugo adds commercial catalyst heading into 2026.
Low beta 0.37 and 2.2% dividend yield appeal investors.
Repatah revenue grew 44% to $870 million in Q4.
Amgen non-GAAP EPS $5.29 beat estimate of $4.83.
Rinzimetostat showed 55% response rate in prostate cancer trials.
Oric holds $392.3 million cash runway into late 2028.
Everest Financial Group LLC established a new position in Amgen Inc. (NASDAQ: AMGN) during the first quarter, purchasing 1,505 shares valued at approximately $530,000 per its latest Form 13F filing. Several other institutional investors also adjusted their holdings recently, including Anfield Capital Management LLC which increased its stake by 1,000% to own 77 shares worth $25,000, and Dogwood Wealth Management LLC which raised its position by 275% to hold 75 shares valued at $25,000.
Amgen reported strong quarterly financial results announced on April 30th, with revenue of $8.62 billion representing a 5.8% year-over-year increase. The company posted earnings per share of $5.15, beating analyst consensus estimates of $4.77 by $0.38. Key financial metrics included a net margin of 20.96% and a return on equity of 137.41%, while the firm provided full-year 2026 guidance ranging between $21.70 and $23.10 per share.
Analyst sentiment remains mixed following the earnings release, with Royal Bank of Canada maintaining a positive rating while Wall Street Zen downgraded the stock from buy to hold. Morgan Stanley lowered its price target to $333.00 with an equal weight rating, whereas Guggenheim raised its target to $343.00 but kept a neutral stance. The consensus rating is currently Hold with a price target of $356.62, and insider trading saw SVP Nancy A. Grygiel sell 1,237 shares for approximately $400,454.
📈 Everest Financial Group bought 1,505 shares worth $530,000 in Q1.
📊 Anfield Capital Management increased holdings by 1,000% to own 77 shares.
💰 Amgen reported $8.62B revenue, beating estimates with $5.15 EPS.
📉 Wall Street Zen downgraded stock from buy to hold on June 27th.
👤 SVP Nancy Grygiel sold 1,237 shares for $400,454 in May.
📈 Everest Financial Group LLC initiated a new position in Amgen Inc. by buying 1,505 shares valued at roughly $530,000 during the first quarter.
📊 Anfield Capital Management LLC significantly increased its holdings by 1,000% to own 77 shares worth $25,000 in the fourth quarter.
💰 Amgen reported quarterly revenue of $8.62 billion, which was up 5.8% year-over-year compared to analyst expectations of $8.58 billion.
📉 The company beat earnings estimates with $5.15 EPS versus a consensus of $4.77, achieving a net margin of 20.96%.
🎯 Amgen provided full-year 2026 guidance for EPS between $21.70 and $23.10, slightly below the average analyst target of $22.31.
📉 Wall Street Zen downgraded Amgen from a buy to a hold rating in a report dated June 27th.
📉 Morgan Stanley decreased its price target from $340.00 to $333.00 and assigned an equal weight rating on July 8th.
📈 Guggenheim raised its price target to $343.00 but maintained a neutral rating in a report from July 13th.
👤 Senior Vice President Nancy A. Grygiel sold 1,237 shares for approximately $400,454 on May 4th, reducing her position by 15%.
🏛️ Institutional ownership stands at 76.50%, with insider ownership currently at 0.85% of the total stock.
Bullish Signals
Amgen beat earnings with $5.15 EPS vs $4.77 estimate.
Net margin hit 20.96% and ROE reached 137.41%.
Revenue grew 5.8% YoY to $8.62 billion.
Everest Financial Group initiated a new position.
Anfield Capital increased holdings by 1,000%.
Risk Factors
Wall Street Zen downgraded Amgen from buy to hold.
Morgan Stanley lowered price target to $333.00.
Consensus target $356.62 below recent high targets.
SVP Nancy Grygiel sold 15% of holdings.
Bullish Signals
Amgen beat quarterly earnings expectations significantly, reporting $5.15 EPS compared to the consensus estimate of $4.77.
The company achieved a robust net margin of 20.96% and a high return on equity of 137.41% for the quarter.
Revenue grew by 5.8% year-over-year to reach $8.62 billion, exceeding analyst forecasts of $8.58 billion.
Everest Financial Group LLC initiated a new position in the stock, indicating institutional interest.
Anfield Capital Management LLC increased its holdings by 1,000%, signaling strong confidence from this specific hedge fund.
Risk Factors
Wall Street Zen downgraded Amgen from a buy to a hold rating, reflecting some caution among analysts.
Morgan Stanley lowered its price target from $340.00 to $333.00 and assigned an equal weight rating.
The consensus analyst price target of $356.62 is below the recent high targets mentioned by other firms like Guggenheim.
Senior Vice President Nancy A. Grygiel sold a significant portion of her holdings, reducing her position by 15%.
Andra AP fonden reduced its position in Amgen Inc. (NASDAQ: AMGN) by 18.9% during the first quarter, selling 11,734 shares to hold a remaining stake of 50,366 shares valued at $17.72 million. While this major institutional investor trimmed its holdings, several smaller hedge funds and wealth management firms increased their stakes significantly in the fourth quarter or first quarter, though their absolute share counts remain very low, ranging from 7 to 97 shares.
Amgen's stock traded at $364.17 on Tuesday, trading above its 50-day moving average of $348.38 but below its 200-day average of $350.78. The company maintains a market capitalization of $196.55 billion with a P/E ratio of 25.34 and a beta of 0.41. Financial metrics indicate a quick ratio of 1.01 and a current ratio of 1.26, while the debt-to-equity ratio stands at 5.65.
Analyst sentiment remains mixed with a consensus target price of $356.62 and an average rating of 'Hold.' Recent actions include Daiwa Securities Group lowering its price target to $390 with an 'outperform' rating, Argus decreasing its target to $375 but maintaining a 'buy' rating, and UBS raising its target to $420 with a 'buy' rating. Insider trading activity saw SVP Nancy A. Grygiel sell 1,237 shares in May for approximately $400,454.
📉 Andra AP cut holdings by 18.9% to $17.72 million stake.
📈 Anfield Capital boosted position by 1,000% to 77 shares.
💰 Stock trades at $364.17 with $196.55 billion market cap.
🎯 Analyst consensus target is $356.62 with 'Hold' rating.
🏢 Institutional investors own 76.50% of Amgen's outstanding stock.
📉 Andra AP fonden cut its Amgen holdings by 18.9% in Q1, reducing its stake to 50,366 shares worth $17.72 million.
📈 Several smaller institutional investors increased their stakes, with Anfield Capital boosting its position by 1,000% to own 77 shares.
💰 Amgen stock opened at $364.17, trading above the 50-day moving average of $348.38 and below the 200-day average of $350.78.
📊 The company has a market cap of $196.55 billion, a P/E ratio of 25.34, and a debt-to-equity ratio of 5.65.
🎯 Analyst consensus target price is $356.62 with an average rating of 'Hold' based on data from MarketBeat.
📉 Daiwa Securities Group lowered its price target to $390 while maintaining an 'outperform' rating in a May 13th report.
📈 UBS Group raised its price target to $420 and assigned a 'buy' rating in a July 13th report.
📉 Argus decreased its price target to $375 but retained a 'buy' rating in a May 20th research note.
💼 SVP Nancy A. Grygiel sold 1,237 shares in May for $400,454, representing a 15% decrease in her personal position.
🏢 Institutional investors collectively own 76.50% of Amgen's outstanding stock.
Amgen Inc. (NASDAQ: AMGN) saw increased institutional interest in the first quarter of 2026, led by Bessemer Group Inc., which boosted its holdings by 9.9% to own 32,013 shares valued at $11.26 million. Other major funds including Robeco Institutional Asset Management B.V., Fideuram Intesa Sanpaolo Private Banking S.P.A., and Robinhood Asset Management LLC also acquired new stakes or significantly increased their positions during the fourth quarter, with institutional ownership standing at 76.5%.
Analyst sentiment remains mixed following a recent earnings beat where Amgen reported $5.15 EPS against a consensus of $4.77 and revenue of $8.62 billion, up 5.8% year-over-year. While Wall Street Zen downgraded the stock to a 'hold' and Daiwa Securities lowered its price target, other firms like Freedom Capital upgraded it to a 'strong-buy,' resulting in a consensus rating of 'Hold' with a price target of $356.62.
Financially, Amgen maintains strong profitability with a net margin of 20.96% and a return on equity of 137.41%. The company has set full-year 2026 EPS guidance between $21.70 and $23.10, slightly below analyst forecasts of $22.31. Trading at $366.29, the stock carries a market cap of $197.69 billion and a P/E ratio of 25.49, while an insider sale by SVP Nancy Grygiel was disclosed in SEC filings.
📈 Bessemer Group increased Amgen holdings to 32,013 shares worth $11.26 million in Q1.
📊 Robeco lifted position by 10% to 481,453 shares valued at $157.58 million in Q4.
💰 Fideuram and Robinhood acquired new stakes totaling approximately $40 million in Q4.
📉 Wall Street Zen downgraded Amgen to 'hold' while analysts lowered price targets.
🚀 Freedom Capital upgraded Amgen to 'strong-buy' contrasting with mixed analyst consensus.
📈 Bessemer Group Inc. increased its Amgen holdings by 9.9% to 32,013 shares worth $11.26 million during the first quarter.
📊 Robeco Institutional Asset Management B.V. lifted its position by 10.0% in Q4, now owning 481,453 shares valued at $157.58 million.
💰 Fideuram Intesa Sanpaolo Private Banking S.P.A. and Robinhood Asset Management LLC acquired new stakes worth approximately $22.44 million and $17.53 million respectively in Q4.
📉 Wall Street Zen downgraded Amgen from 'buy' to 'hold' on June 27th, while Daiwa Securities cut its price target from $410 to $390.
🚀 Freedom Capital upgraded Amgen to a 'strong-buy' rating on May 7th, contrasting with the mixed analyst consensus.
💵 Amgen reported Q1 EPS of $5.15, beating estimates by $0.38, and revenue of $8.62 billion, up 5.8% year-over-year.
📈 The company achieved a net margin of 20.96% and a return on equity of 137.41% in the most recent quarter.
🎯 Amgen set FY 2026 EPS guidance between $21.70 and $23.10, slightly below analyst forecasts of $22.31.
📉 Insider SVP Nancy A. Grygiel sold 1,237 shares for $400,454 on May 4th, reducing her ownership by 15%.
🏢 Institutional investors own 76.5% of Amgen's outstanding stock as of the latest filings.
Bullish Signals
Amgen beat earnings with $5.15 EPS vs $4.77 consensus.
Freedom Capital upgraded stock to strong-buy rating.
Risk Factors
Wall Street Zen downgraded Amgen from buy to hold.
Daiwa lowered price target from $410.00 to $390.00.
2026 EPS guidance of $21.70-$23.10 misses analyst forecasts.
SVP Nancy Grygiel sold 15% of her holdings.
Bullish Signals
Amgen beat quarterly earnings expectations with $5.15 EPS versus a consensus of $4.77, demonstrating strong operational performance.
Revenue grew by 5.8% year-over-year to reach $8.62 billion, indicating continued demand for the company's biologic medicines.
The company maintains robust profitability metrics with a net margin of 20.96% and an impressive return on equity of 137.41%.
Multiple institutional investors including Bessemer Group, Robeco, and Robinhood increased their stakes, signaling confidence in the stock's long-term prospects.
Freedom Capital upgraded Amgen to a 'strong-buy' rating, adding to the bullish sentiment from other analysts.
Risk Factors
Wall Street Zen downgraded Amgen from a 'buy' to a 'hold' rating, reflecting some caution among analysts regarding current valuation or growth prospects.
Daiwa Securities lowered its price target from $410.00 to $390.00, suggesting potential downside pressure or revised expectations for the stock.
Amgen's full-year 2026 EPS guidance of $21.70-$23.10 is below analyst forecasts of $22.31, indicating a conservative outlook from management.
An insider sale by SVP Nancy Grygiel, who reduced her holdings by 15%, may signal a lack of immediate confidence at the executive level, though this is a small position relative to total shares.
AIA Group Ltd increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 11.2% during the first quarter, purchasing an additional 2,815 shares to own a total of 27,962 shares valued at $9.838 million. This filing highlights continued institutional interest alongside other hedge funds like Anfield Capital Management and Dogwood Wealth Management, which also adjusted their stakes significantly in the fourth quarter.
Amgen reported strong quarterly financial results ending April 30th, with revenue of $8.62 billion, a 5.8% year-over-year increase that beat analyst expectations. The company posted earnings per share of $5.15, surpassing the consensus estimate of $4.77, and achieved a net margin of 20.96%. Analysts have set an average price target of $356.62, with the stock currently trading around $366.
Analyst sentiment remains mixed but generally positive regarding the company's fundamentals. Freedom Capital upgraded Amgen to a 'strong-buy' rating, while Piper Sandler maintained an 'overweight' stance. However, Wall Street Zen downgraded the stock to a 'hold'. The company maintains a market capitalization of $197.69 billion and has provided FY 2026 EPS guidance between $21.70 and $23.10.
📈 AIA Group increased Amgen holdings by 11.2% to 27,962 shares.
💰 Q1 revenue hit $8.62 billion, up 5.8% year-over-year.
📊 EPS reached $5.15, beating estimates by $0.38.
🏦 Institutional ownership remains at 76.5%.
🎯 Average analyst price target is $356.62.
📈 AIA Group Ltd increased its Amgen holdings by 11.2% in Q1, adding 2,815 shares to a total position of 27,962 shares.
💰 Amgen reported Q1 revenue of $8.62 billion, beating estimates and growing 5.8% year-over-year.
📊 The company posted EPS of $5.15, exceeding analyst consensus estimates of $4.77 by $0.38.
🏦 Institutional ownership stands at 76.5%, with several hedge funds adjusting positions in Q4 and Q1.
📉 Wall Street Zen downgraded Amgen from 'buy' to 'hold', while Freedom Capital upgraded it to 'strong-buy'.
🎯 Analysts maintain an average price target of $356.62 for the stock.
📈 Amgen provided FY 2026 EPS guidance ranging from $21.70 to $23.10.
💼 SVP Nancy A. Grygiel sold 1,237 shares in a transaction valued at approximately $400,454.
Bullish Signals
Amgen beat EPS estimates at $5.15 vs $4.77 consensus.
Revenue grew 5.8% YoY to $8.62 billion.
High ROE of 137.41% and net margin of 20.96%.
Freedom Capital upgraded rating to strong-buy.
Institutional investors increased stakes in the stock.
Risk Factors
Wall Street Zen downgraded Amgen from buy to hold.
SVP Nancy A. Grygiel sold 15% of her holdings.
High P/E of 25.49 and PEG of 3.71.
Bullish Signals
Amgen beat quarterly earnings estimates with EPS of $5.15 versus the consensus of $4.77.
Revenue grew 5.8% year-over-year to reach $8.62 billion, exceeding analyst expectations of $8.58 billion.
The company achieved a high return on equity of 137.41% and a net margin of 20.96%.
Freedom Capital upgraded its rating from 'hold' to 'strong-buy', indicating improved confidence in the stock.
Piper Sandler reaffirmed an 'overweight' rating, signaling continued institutional support.
Institutional investors like AIA Group Ltd increased their stakes, demonstrating sustained interest.
Risk Factors
Wall Street Zen downgraded Amgen from a 'buy' to a 'hold' rating in late June.
SVP Nancy A. Grygiel sold 15% of her holdings, reducing her stake by 1,237 shares.
The stock trades at a P/E ratio of 25.49 and a PEG ratio of 3.71, which may be considered high relative to growth.
Equities research analysts at Erste Group Bank have reduced their full-year 2027 earnings per share (EPS) estimate for Amgen Inc. to $23.58, down from a previous forecast of $23.62. The analyst maintains a 'Hold' rating on the stock, which currently trades with a consensus EPS estimate of $22.31. This adjustment reflects a slight downward revision in long-term growth expectations for the biotechnology company.
Amgen recently reported strong quarterly results for the quarter ended April 30th, posting EPS of $5.15 against a consensus of $4.77 and revenue of $8.62 billion, beating expectations of $8.58 billion. The company achieved a net margin of 20.96% and a return on equity of 137.41%, with revenue growing 5.8% year-over-year. Management has set full-year 2026 guidance between $21.70 and $23.10 per share.
Analyst sentiment remains mixed, with Royal Bank of Canada reaffirming a 'positive' rating while Morgan Stanley lowered its price target to $333.00 and Piper Sandler reiterated an 'overweight' stance. The stock currently has an average analyst rating of 'Hold' with a price target of $356.62, trading near its 50-day moving average of $347.69.
📉 Erste Group Bank lowered FY2027 EPS estimate to $23.58.
📈 Q1 EPS beat expectations at $5.15 vs $4.77 consensus.
💰 Net margin reached 20.96% with ROE of 137.41%.
🎯 FY2026 guidance set between $21.70 and $23.10 EPS.
🏦 Morgan Stanley cut price target to $333.00.
📉 Erste Group Bank lowered FY2027 EPS estimates for Amgen to $23.58 from $23.62 while maintaining a 'Hold' rating.
📈 The company beat Q1 earnings expectations with $5.15 EPS and revenue of $8.62 billion, exceeding the consensus of $4.77 EPS and $8.58 billion.
💰 Amgen reported a net margin of 20.96% and a return on equity of 137.41% during the quarter ended April 30th.
🎯 Full-year 2026 guidance stands at $21.70-$23.10 EPS, with revenue up 5.8% year-over-year to $8.62 billion.
🏦 Morgan Stanley reduced its price target to $333.00 and set an 'equal weight' rating on the stock.
📊 Royal Bank of Canada reissued a 'positive' rating, while Piper Sandler reiterated an 'overweight' recommendation.
📉 Truist Financial raised its price target to $340.00 but maintained a 'Hold' rating on the shares.
🏛️ Institutional investors own 76.50% of the company's outstanding stock as of the latest filings.
📉 SVP Nancy A. Grygiel sold 1,237 shares for approximately $400,454 in a transaction disclosed to the SEC.
📈 The stock trades at a PEG ratio of 3.76 with a market capitalization of $197.69 billion.
Bullish Signals
Amgen beat EPS estimates with $5.15 versus $4.77 consensus.
Revenue grew 5.8% YoY to $8.62 billion, beating expectations.
Net margin reached 20.96% with ROE of 137.41%.
Royal Bank of Canada reissued a positive rating on the stock.
Piper Sandler reiterated an overweight rating for sustained bullish sentiment.
Risk Factors
Erste Group Bank reduced FY2027 EPS forecast to $23.58.
Morgan Stanley lowered price target from $340.00 to $333.00.
Weiss Ratings downgraded stock from 'buy (b)' to 'buy (b-)'.
Bullish Signals
Amgen beat quarterly earnings estimates significantly, reporting $5.15 EPS versus the consensus of $4.77.
Revenue grew 5.8% year-over-year to $8.62 billion, surpassing analyst expectations of $8.58 billion.
The company demonstrated strong profitability with a net margin of 20.96% and an impressive return on equity of 137.41%.
Royal Bank of Canada has reissued a 'positive' rating on the stock, signaling continued confidence in the business model.
Piper Sandler reiterated its 'overweight' rating, indicating sustained bullish sentiment from major investment banks.
Truist Financial increased its price target to $340.00, reflecting optimism regarding future performance potential.
Risk Factors
Erste Group Bank reduced its FY2027 EPS forecast to $23.58, indicating a slight downgrade in long-term growth expectations.
Morgan Stanley lowered its price target from $340.00 to $333.00 and adjusted its rating to 'equal weight', suggesting caution.
Weiss Ratings downgraded the stock from a 'buy (b)' to a 'buy (b-)', reflecting a minor reduction in investment grade status.
SVP Nancy A. Grygiel sold 1,237 shares for $400,454, representing a 15% decrease in her personal ownership stake.
Amgen Inc. reported second-quarter 2012 financial results showing a 13% revenue increase to $4.5 billion and adjusted earnings rising 34% to $1.83 per share, significantly beating Thomson Reuters estimates of $1.54 EPS and $4.08 billion in revenue.
The company raised its full-year 2012 guidance for total revenue to between $16.9 billion and $17.2 billion, with adjusted earnings targets set at $6.20 to $6.35 per share. This new range places the company's expectations above the consensus estimates of approximately $6.15 EPS and $16.4 billion in revenue.
Amgen attributed 8% product sales growth to strong portfolio performance and recognized $206 million in other revenues from a modified agreement with Takeda regarding Motesanib development rights. The company generated approximately $2.2 billion in free cash flow for the quarter while maintaining a long-term debt balance of nearly $22 billion.
Looking ahead, Amgen announced that four Phase 2 studies for AMG 145 have successfully completed, with plans to initiate Phase 3 development in early 2013. Following the earnings release, shares closed up 0.7% at $79.29 and traded higher than $80, approaching their 52-week high of $80.25.
Analysts are expected to raise price targets following the strong results, as the stock outperformed the consensus target of nearly $76.00. The company's share repurchase activity has also contributed to a lower share count, further supporting adjusted earnings per share growth.
📈 Q2 2012 revenue hit $4.5 billion, up 13%.
💰 Adjusted EPS rose 34% to $1.83, beating estimates.
🚀 Full-year guidance raised for revenue and EPS targets.
💊 Takeda deal added $206 million in other revenues.
📉 Generated $2.2 billion free cash flow this quarter.
📈 Amgen reported Q2 2012 revenue of $4.5 billion, representing a 13% year-over-year gain.
💰 Adjusted earnings per share rose 34% to $1.83, significantly beating the consensus estimate of $1.54.
🚀 The company raised its full-year 2012 revenue guidance to $16.9-$17.2 billion and EPS guidance to $6.20-$6.35.
💊 Amgen recognized $206 million in other revenues from a modified agreement with Takeda for Motesanib development rights.
📉 The company generated approximately $2.2 billion in free cash flow during the quarter.
🔬 Four Phase 2 studies for AMG 145 completed successfully, with Phase 3 trials planned to start in early 2013.
📊 Shares closed up 0.7% at $79.29 and traded above $80 after the earnings announcement.
🏦 Amgen maintains a long-term debt balance of approximately $22 billion.
📉 Share repurchase activity has reduced the share count, contributing to higher adjusted EPS.
👀 Analyst price targets are expected to be raised following the strong performance and beat.
Bullish Signals
Revenue grew 13% year-over-year to $4.5 billion.
Adjusted EPS surged 34% to $1.83.
Full-year revenue guidance raised to $16.9-$17.2 billion.
EPS guidance increased to $6.20-$6.35 range.
Product sales grew 8% across all therapeutic areas.
Risk Factors
Significant long-term debt balance of approximately $22 billion.
Bank of New York Mellon Corp reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 2.9% in the first quarter, selling 113,573 shares to hold a position valued at approximately $1.33 billion. While several smaller institutional investors like Anfield Capital and Dogwood Wealth Management increased their holdings significantly, these positions remain negligible in absolute terms compared to major holders. Hedge funds and other institutions collectively own 76.50% of the company's outstanding stock.
Analyst sentiment regarding Amgen remains mixed with a consensus price target of $356.62. Argus Capital Group lowered its price objective from $400 to $375 while maintaining a 'buy' rating, whereas Wall Street Zen downgraded the stock from 'buy' to 'hold'. Other major firms like BMO Capital Markets and Guggenheim maintained their respective 'outperform' and 'neutral' ratings with targets near current market levels.
Financially, Amgen reported strong quarterly results for the quarter ended April 30th, posting $5.15 in earnings per share which beat consensus estimates of $4.77. Revenue reached $8.62 billion, a 5.8% year-over-year increase that also surpassed analyst expectations of $8.58 billion. The company achieved a net margin of 20.96% and a return on equity of 137.41%, with shares trading at a P/E ratio of 24.94.
The stock currently trades around $358, sitting above its 50-day moving average but slightly below its 200-day average. Management provided full-year 2026 earnings guidance ranging between $21.70 and $23.10 per share, which aligns closely with analyst expectations of $22.31. Insider trading activity saw SVP Nancy Grygiel sell a portion of her holdings, reducing her stake by 15%.
📉 BNY Mellon sold shares but keeps a $1.33 billion position.
💰 Q1 EPS hit $5.15, beating estimates and growing revenue 5.8%.
🎯 Full-year 2026 EPS guidance ranges from $21.70 to $23.10.
📉 Analysts lowered price targets while maintaining mixed buy/hold ratings.
🏦 Stock trades at a P/E of 24.94 with a $193.39B market cap.
📉 Bank of New York Mellon Corp reduced its Amgen stake by 2.9% in Q1, selling 113,573 shares while retaining a $1.33 billion position.
📈 Smaller institutional investors including Anfield Capital and Dogwood Wealth Management significantly increased their holdings in the fourth quarter.
📊 Analyst consensus price target stands at $356.62 with an average rating of 'Hold' based on data from MarketBeat.
💰 Amgen reported Q1 EPS of $5.15, beating estimates by $0.38 and generating revenue of $8.62 billion.
📈 Revenue grew 5.8% year-over-year to exceed analyst expectations of $8.58 billion for the quarter.
💹 The company achieved a net margin of 20.96% and a return on equity of 137.41% during the reported period.
🎯 Full-year 2026 EPS guidance is set between $21.70 and $23.10, aligning closely with analyst forecasts of $22.31.
📉 Argus Capital Group lowered its price target from $400 to $375 while maintaining a 'buy' rating on the stock.
📉 Wall Street Zen downgraded Amgen from 'buy' to 'hold' in a recent research note dated June 27th.
🏦 BMO Capital Markets reaffirmed an 'outperform' rating with a $400 price target issued on July 1st.
📉 SVP Nancy Grygiel sold 1,237 shares worth approximately $400,454 in a transaction completed on May 4th.
📊 Amgen's stock trades at a P/E ratio of 24.94 with a market capitalization of $193.39 billion.
Bullish Signals
Q1 EPS beat consensus by $0.38 at $5.15.
Revenue grew 5.8% YoY to $8.62 billion.
Net margin reached 20.96% with ROE of 137.41%.
Full-year 2026 EPS guidance aligns with analyst expectations.
BMO reaffirmed 'outperform' rating with $400 price target.
Risk Factors
BNY Mellon reduced stake by 2.9% in Q1.
Wall Street Zen downgraded Amgen to 'hold'.
Argus lowered price objective from $400 to $375.
Stock trades below 200-day moving average of $350.
Bullish Signals
Amgen reported Q1 EPS of $5.15, significantly beating the consensus estimate of $4.77 by $0.38.
Revenue reached $8.62 billion, surpassing analyst estimates of $8.58 billion and growing 5.8% year-over-year.
The company achieved a robust net margin of 20.96% and an impressive return on equity of 137.41%.
Full-year 2026 EPS guidance of $21.70-$23.10 aligns closely with analyst expectations of $22.31.
BMO Capital Markets reaffirmed an 'outperform' rating and set a high price target of $400.
Risk Factors
Bank of New York Mellon Corp, a major institutional holder, reduced its stake by 2.9% in the first quarter.
Wall Street Zen downgraded Amgen from a 'buy' to a 'hold' rating in late June.
Argus Capital Group lowered its price objective from $400 to $375 despite maintaining a buy rating.
The stock trades below its 200-day moving average of $350.00 while hovering near the 50-day average.
This article presents a bullish investment thesis on Amgen Inc. (AMGN), noting the stock was trading at $344.57 as of June 9, 2026, with trailing and forward P/E ratios of 23.98 and 15.48 respectively. The core argument suggests that while the company faces a loss-of-exclusivity (LOE) cliff from legacy assets like Enbrel, the market underappreciates the strength and diversification of its replacement engine.
The bullish case highlights Amgen's evolved biosimilars platform as a meaningful profit contributor that leverages decades of manufacturing expertise to create a durable barrier to entry. Additionally, improving reimbursement dynamics for Repatha and the growth potential of TEZSPIRE in severe asthma are cited as underappreciated growth vectors that reinforce demand despite competitive pressures.
Despite elevated leverage from the Horizon acquisition, Amgen's robust free cash flow generation is deemed sufficient to service debt while funding innovation and shareholder returns. Management's conservative mid-single-digit revenue growth trajectory is viewed as offering embedded upside relative to consensus expectations, creating a compelling risk-reward profile where sentiment lags fundamentals.
The article concludes that Amgen offers a setup where earnings power is materially underappreciated, combining resilient cash flows with pipeline optionality beyond LOE headwinds. While the author notes hedge fund holdings have slightly declined and suggests AI stocks may offer higher returns, the primary focus remains on AMGN's specific financial resilience and strategic positioning.
📈 Stock trades at $344.57 with forward P/E of 15.48 as of June 2026.
🛡️ Biosimilars platform now monetizes legacy asset erosion profitably.
💊 Repatha gains from better reimbursement and cardiovascular risk awareness.
🌬️ TEZSPIRE offers growth in the underpenetrated severe asthma market.
💰 Strong free cash flow services debt and funds innovation.
📈 Amgen stock was trading at $344.57 with a forward P/E of 15.48 as of June 9, 2026.
🛡️ The company's biosimilars platform has evolved into a meaningful profit contributor that monetizes legacy asset erosion.
💊 Repatha benefits from improving reimbursement dynamics and expanding cardiovascular risk awareness.
🌬️ TEZSPIRE adds growth potential in the underpenetrated severe asthma biologics market.
💰 Robust free cash flow generation allows Amgen to service debt while funding innovation.
📉 Management's mid-single-digit revenue guidance is viewed as conservative relative to pipeline optionality.
🏛️ The Horizon acquisition has elevated leverage, but cash flows remain sufficient for operations.
📊 Hedge fund portfolios holding AMGN decreased from 70 in Q1 to 65 by the end of the first quarter.
🔍 Analysts believe market sentiment currently lags behind Amgen's underlying fundamentals and earnings power.
Bullish Signals
Biosimilars platform now meaningfully contributes profits.
Repayment dynamics and risk awareness boost Repatha demand.
TEZSPIRE offers growth in underpenetrated severe asthma.
Robust free cash flow services debt and funds innovation.
Legacy assets like Enbrel face loss-of-exclusivity cliffs.
Otezla faces competitive market pressure.
Horizon acquisition elevated company leverage levels.
Hedge fund portfolios dropped from 70 to 65.
Bullish Signals
Amgen's biosimilars platform has evolved into a meaningful profit contributor, leveraging decades of manufacturing expertise to create a durable barrier to entry.
Improving reimbursement dynamics for Repatha and expanding cardiovascular risk awareness are reinforcing demand for its LDL-lowering therapies.
TEZSPIRE represents an underappreciated growth vector in severe asthma where biologics remain underpenetrated.
Amgen's robust free cash flow generation is sufficient to comfortably service debt while still funding innovation and shareholder returns.
Management's mid-single-digit revenue growth trajectory appears conservative relative to pipeline optionality, suggesting embedded upside to consensus expectations.
The company possesses a biosimilars franchise that monetizes rather than competes against biologic erosion from legacy assets.
Risk Factors
Amgen is facing a widely acknowledged loss-of-exclusivity (LOE) cliff with legacy assets such as Enbrel already in decline.
Otezla is currently under competitive pressure from the market.
The Horizon acquisition has elevated the company's leverage levels.
Hedge fund interest has declined, with portfolios holding AMGN dropping from 70 to 65 between Q1 and the end of the first quarter.
Elevation Point Wealth Partners LLC significantly increased its position in Amgen Inc. (NASDAQ:AMGN) by 91.9% in the first quarter, purchasing an additional 10,271 shares to hold a total of 21,443 shares valued at $7.545 million. Other institutional investors also adjusted their stakes, with Brighton Jones LLC increasing holdings by 23.5%, Schnieders Capital Management by 29.3%, and Ieq Capital by 5.1%. Collectively, institutional investors own 76.5% of the company's outstanding stock.
Amgen recently reported strong financial results for the quarter ended April 30th, posting $5.15 in earnings per share which beat analyst consensus estimates of $4.77 by $0.38. The company generated revenue of $8.62 billion, a 5.8% increase year-over-year, with a net margin of 20.96% and a return on equity of 137.41%. Management has provided full-year 2026 guidance for EPS between $21.70 and $23.10, while Wall Street analysts currently forecast an average EPS of $22.39.
Analyst sentiment remains mixed with a consensus rating of 'Hold' and an average price target of $355.50. Recent actions include Daiwa Securities Group lowering its target price to $390 while maintaining an 'outperform' rating, whereas Wall Street Zen downgraded the stock from 'buy' to 'hold'. Insider trading activity saw SVP Nancy A. Grygiel sell 1,237 shares at an average price of $323.73, reducing her personal ownership by 15%.
📈 Elevation Point Wealth boosted Amgen stake by 91.9% in Q1.
💰 Company reported $5.15 EPS, beating analyst estimates of $4.77.
📊 Revenue reached $8.62 billion, up 5.8% year-over-year.
🎯 FY 2026 EPS guidance ranges from $21.70 to $23.10.
🏢 Institutional ownership stands at 76.5% of total outstanding stock.
📈 Elevation Point Wealth Partners LLC boosted its Amgen stake by 91.9% in Q1, adding 10,271 shares to a total holding of 21,443 shares.
💰 The company reported $5.15 EPS for the quarter, beating analyst estimates of $4.77 by $0.38.
📊 Revenue reached $8.62 billion, representing a 5.8% year-over-year increase.
🎯 Amgen provided FY 2026 guidance with EPS expectations ranging from $21.70 to $23.10.
📉 Wall Street Zen downgraded the stock from 'buy' to 'hold', contributing to a consensus 'Hold' rating.
💸 SVP Nancy A. Grygiel sold 1,237 shares for approximately $400,454 in a transaction on May 4th.
🏢 Institutional ownership stands at 76.5% of the company's total outstanding stock.
📉 Daiwa Securities Group lowered its price target to $390 while maintaining an 'outperform' rating.
Bullish Signals
EPS beat estimates at $5.15 vs $4.77 consensus.
Revenue grew 5.8% YoY to $8.62 billion.
Net margin reached 20.96% with ROE of 137.41%.
Investor Elevation Point Wealth increased position by 91.9%.
Daiwa Securities maintains 'outperform' rating for long-term optimism.
Risk Factors
Zen downgraded to 'hold' on June 27th.
Guggenheim cut target to $340 and rated neutral.
SVP Grygiel sold 1,237 shares, dropping ownership 15%.
Consensus target of $355.50 exceeds recent insider sale price.
Bullish Signals
Amgen beat quarterly earnings estimates with EPS of $5.15 versus a consensus of $4.77, demonstrating strong profitability.
Revenue grew by 5.8% year-over-year to reach $8.62 billion, indicating solid top-line growth.
The company achieved a high net margin of 20.96% and an impressive return on equity of 137.41%.
Major institutional investor Elevation Point Wealth Partners increased its position by 91.9%, signaling confidence in the stock.
Daiwa Securities Group maintains an 'outperform' rating despite lowering the price target, suggesting continued long-term optimism.
Risk Factors
Wall Street Zen downgraded the stock from a 'buy' to a 'hold' rating on June 27th.
Guggenheim lowered its price target from $351.00 to $340.00 and assigned a 'neutral' rating.
SVP Nancy A. Grygiel sold 1,237 shares of company stock, reducing her personal ownership by 15%.
The consensus analyst price target of $355.50 is below the recent trading price mentioned in insider transactions ($323.73 average sale price), though this reflects a discount rather than a direct negative signal.
Forum Financial Management LP reduced its stake in Amgen Inc. (AMGN) by selling 2,792 shares during the first quarter, representing a 0.8% trim of its position. The firm now holds approximately 347,970 shares valued at $122.4 million, which constitutes about 1.7% of its total portfolio and ranks as its 11th largest holding.
Despite the institutional sell-off by Forum Financial Management LP, major investors like Norges Bank, Capital World Investors, State Street Corp, Geode Capital Management LLC, and Amundi significantly increased their holdings in the fourth quarter. Collectively, these institutions own 76.5% of the company's outstanding stock, indicating strong continued interest from large-scale asset managers.
Amgen reported strong quarterly financial results for the period ending April 30th, beating analyst estimates with earnings per share (EPS) of $5.15 versus a consensus of $4.77 and revenue of $8.62 billion against an estimate of $8.58 billion. The company achieved a net margin of 20.96% and reported year-over-year revenue growth of 5.8%, while setting forward guidance for FY 2026 EPS between $21.70 and $23.10.
Analyst sentiment regarding AMGN remains mixed, with a consensus rating of 'Hold' and a target price of $354.42. While some firms like Morgan Stanley raised their price targets, others such as Daiwa Securities lowered theirs. Insider trading activity saw SVP Nancy A. Grygiel sell 1,237 shares in May, reducing her personal stake by 15%.
📉 Forum Financial Management LP sold 2,792 shares to hold a $122.4M stake.
📈 Major institutions like Norges Bank significantly increased their Amgen holdings in Q4.
💰 Amgen beat EPS estimates with $5.15 results and $8.62B revenue.
📊 Net margin reached 20.96% with 5.8% year-over-year revenue growth.
🎯 Analyst consensus is 'Hold' with a price target of $354.42.
📉 Forum Financial Management LP trimmed its Amgen position by 0.8%, selling 2,792 shares to end the quarter with a $122.4 million stake.
📈 Major institutional investors including Norges Bank, Capital World Investors, and State Street Corp significantly increased their holdings in Q4.
💰 Amgen beat quarterly EPS estimates of $4.77 with actual results of $5.15 and revenue of $8.62 billion.
📊 The company reported a net margin of 20.96% and achieved 5.8% year-over-year revenue growth.
🎯 Analyst consensus remains 'Hold' with a price target of $354.42, though targets vary from $332 to $410 across different firms.
👤 SVP Nancy A. Grygiel sold 1,237 shares in May, reducing her personal holding by 15% for a total value of roughly $400k.
📅 Amgen provided FY 2026 guidance expecting EPS between $21.70 and $23.10.
🏢 Institutional ownership stands at 76.5%, with the top holders collectively owning over $25 billion in stock.
Bullish Signals
Amgen beat EPS estimates with $5.15 vs $4.77 consensus.
Revenue exceeded expectations at $8.62 billion versus $8.58 estimate.
Net margin remained robust at 20.96%.
Institutional investors like Capital World increased stakes significantly in Q4.
Return on equity reached a high of 137.41%.
Revenue grew by 5.8% year-over-year.
Risk Factors
Forum Financial Management LP reduced stake by 0.8% in Q1.
Analyst consensus 'Hold' with $354.42 target price suggests limited upside.
Daiwa Securities lowered price objective from $410 to $390.
SVP Nancy Grygiel sold 1,237 shares, reducing position by 15%.
Bullish Signals
Amgen beat quarterly earnings per share estimates by $0.38, reporting $5.15 EPS against a consensus of $4.77.
The company exceeded revenue expectations with $8.62 billion reported versus an analyst estimate of $8.58 billion.
Net margin remained robust at 20.96%, demonstrating strong profitability on the generated revenue.
Major institutional investors like Capital World Investors and State Street Corp increased their stakes significantly in Q4.
The company achieved a high return on equity of 137.41% for the quarter.
Revenue grew by 5.8% year-over-year, indicating continued top-line expansion.
Risk Factors
Forum Financial Management LP reduced its stake in Amgen by 0.8% during the first quarter.
Analyst consensus rating is 'Hold' with a target price of $354.42, suggesting limited immediate upside according to Wall Street averages.
Daiwa Securities Group lowered its price objective from $410.00 to $390.00 in recent research.
SVP Nancy A. Grygiel sold 1,237 shares of stock in May, reducing her personal position by 15%.
Fort Washington Investment Advisors Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 5.2% during the first quarter, purchasing an additional 4,559 shares to hold a total position of 92,090 shares valued at $32.4 million. This move aligns with several other institutional investors who recently adjusted their holdings, including significant percentage increases from Dogwood Wealth Management, Anfield Capital Management, and Tower View Wealth Management, though these smaller firms hold negligible absolute positions.
Amgen reported strong quarterly financial results released on April 30th, beating analyst expectations for both earnings per share and revenue. The company posted $5.15 EPS compared to a consensus of $4.77 and generated $8.62 billion in revenue versus an estimate of $8.58 billion. Revenue grew 5.8% year-over-year, driven by the company's focus on biologics for oncology, nephrology, and other serious illnesses.
The stock has maintained a market capitalization of $193.54 billion with a P/E ratio of 24.96. While SVP Nancy A. Grygiel sold approximately $400,454 worth of shares in May, reducing her personal stake by 15%, insider ownership remains low at 0.85%. The company has provided forward guidance for FY 2026 EPS between $21.70 and $23.10, which is slightly below the average analyst expectation of $22.38.
📈 Fort Washington added 4,559 shares, holding 92,090 total valued at $32.4M.
📊 Dogwood Wealth and Anfield Capital increased stakes by 275% and 1,000%.
📉 SVP Nancy Grygiel sold 1,237 shares, reducing her position by 15%.
💰 Amgen Q1 EPS hit $5.15 vs $4.77 estimate; revenue grew 5.8% YoY.
🏥 Company maintains 137.41% ROE, 20.96% net margin, and 76.50% institutional ownership.
📈 Fort Washington Investment Advisors Inc. boosted its Amgen stake by 5.2% in Q1, adding 4,559 shares to a total holding of 92,090 shares.
💰 The position held by Fort Washington is valued at $32.4 million as of the most recent SEC disclosure.
📊 Dogwood Wealth Management increased its stake by 275% in Q4, while Anfield Capital Management raised holdings by 1,000%.
📉 SVP Nancy A. Grygiel sold 1,237 shares for $400,454 on May 4th, reducing her personal position by 15%.
💵 Amgen reported Q1 EPS of $5.15, surpassing the consensus estimate of $4.77 by $0.38.
📈 Revenue reached $8.62 billion in the quarter, exceeding the $8.58 billion consensus and growing 5.8% year-over-year.
🏥 The company maintains a high return on equity of 137.41% and a net margin of 20.96%.
📅 Amgen provided FY 2026 guidance for EPS between $21.70 and $23.10.
🎯 Analysts currently anticipate FY 2026 earnings per share to average $22.38.
🏢 Institutional investors and hedge funds collectively own 76.50% of the company's outstanding stock.
Bullish Signals
Amgen beat EPS ($5.15) and revenue ($8.62B) estimates.
Strong ROE of 137.41% and net margin of 20.96%.
Revenue grew 5.8% year-over-year on continued demand.
Institutional investors increased stakes in the stock.
Amgen beat quarterly consensus estimates for both EPS ($5.15 vs $4.77) and revenue ($8.62B vs $8.58B), demonstrating strong operational execution.
The company achieved a robust return on equity of 137.41% and maintained a healthy net margin of 20.96%.
Revenue grew by 5.8% year-over-year, indicating continued demand for the company's biologic medicines in oncology and other therapeutic areas.
Multiple institutional investors, including Fort Washington Investment Advisors, Dogwood Wealth Management, and Anfield Capital Management, increased their stakes in the stock recently.
Risk Factors
SVP Nancy A. Grygiel sold a significant portion of her holdings (15% decrease) for $400,454, though insider ownership remains low at 0.85%.
The company's FY 2026 guidance range of $21.70-$23.10 EPS is slightly below the average analyst expectation of $22.38.
Piper Sandler and Morgan Stanley have reaffirmed their Overweight ratings on Amgen Inc. (NASDAQ: AMGN), citing the strength of its pharmaceutical pipeline and potential in obesity therapeutics. Piper Sandler maintained a $427 price target, while Morgan Stanley raised its objective to $340 from $332 following the company's acquisition of Horizon.
Analysts highlight dazodalibep, a CD40 ligand-directed fusion protein for Sjogren's syndrome, as an underappreciated asset with Phase III trials concluding in late 2026. The drug targets both moderate-to-severe symptoms and systemic disease activity, bolstering Amgen's immunology portfolio.
Morgan Stanley emphasizes MariTide, a major focus within the company's pipeline for obesity treatment, as a key driver for future stock performance. While acknowledging investment risks, analysts view these developments as significant catalysts for Amgen's growth trajectory.
📈 Piper Sandler reaffirms Overweight rating with $427 price target.
📈 Morgan Stanley maintains Overweight rating, raising target to $340.
💊 Dazodalibep Phase III trials conclude late 2026 for Sjogren's.
🔬 Amgen studies dazodalibep in moderate-to-severe symptoms and systemic disease.
🤝 Horizon acquisition bolsters Amgen's portfolio per Morgan Stanley.
📈 Piper Sandler reaffirmed an Overweight rating and $427 price target for Amgen Inc. (NASDAQ: AMGN).
📈 Morgan Stanley maintained its Overweight rating and increased its price objective to $340 from $332.
💊 Dazodalibep is a CD40 ligand-directed fusion protein for Sjogren's syndrome with Phase III trials concluding in late 2026.
🔬 Amgen is researching dazodalibep across two categories: moderate-to-severe symptoms and systemic disease activity.
🤝 Morgan Stanley notes that Amgen's portfolio is bolstered by its recent acquisition of Horizon.
⚖️ MariTide is identified as a major focus within Amgen's pipeline for obesity treatment.
🏢 Amgen Inc. was founded in 1980 and is headquartered in California.
Bullish Signals
Piper Sandler reaffirmed Overweight rating with $427 price target.
Morgan Stanley increased objective to $340 from $332.
Phase III conclusion for dazodalibep expected late 2026.
Horizon acquisition bolsters portfolio of cutting-edge medications.
MariTide highlighted as major obesity drug focus area.
Bullish Signals
Piper Sandler reaffirmed its Overweight rating with a $427 price target, signaling strong institutional confidence in the company's current valuation.
Morgan Stanley increased its price objective to $340 from $332, indicating a positive revision based on recent corporate developments.
The upcoming Phase III conclusion for dazodalibep in late 2026 represents a significant potential milestone for Amgen's immunology division.
Amgen's acquisition of Horizon is viewed as a strategic move to bolster its portfolio of cutting-edge medications.
MariTide is highlighted as a major focus area, suggesting strong analyst interest in the company's obesity drug potential.
Amgen (AMGN) stock is currently trading at $344.72, which a recent analysis suggests is approximately 2.1% undervalued relative to a calculated fair value of $352.23. This valuation assessment follows a significant legal development where Harbour BioMed's jury found Amgen guilty of willful patent infringement, awarding the competitor $20.2 million in damages.
Despite the recent legal setback, Amgen has demonstrated strong longer-term momentum with a 30.33% one-year total shareholder return and a 68.20% three-year return. The company's share price has gained 5.21% year-to-date, trading close to analyst price targets while maintaining a solid balance sheet and established dividend status.
The bullish thesis relies on Amgen's robust late-stage pipeline featuring high-margin, first-in-class products such as MariTide for obesity and type 2 diabetes, Repatha for cardiovascular health, and multiple bispecific T-cell engagers for oncology. These advancements are expected to drive top-line growth and margin expansion in the coming years.
However, investors must weigh these growth prospects against specific risks including potential tightening of drug pricing pressures and the threat of biosimilar competitors eroding revenue from key franchises faster than anticipated. The market sentiment remains split between concerns over legal liabilities and confidence in the pipeline's future potential.
📉 Stock trades at $344.72, 2.1% undervalued vs $352.23 fair value.
⚖️ Jury verdict awards Harbour BioMed $20.2M for willful infringement.
📈 Delivered 30.33% return last year and 68.20% over three years.
💊 Pipeline features MariTide, Repatha, and oncology bispecific T-cell engagers.
⚠️ Revenue faces headwinds from pricing regulations and biosimilar competition.
📉 Amgen stock is trading at $344.72, representing a 2.1% undervaluation against a calculated fair value of $352.23.
⚖️ Harbour BioMed secured a jury verdict confirming willful infringement by Amgen and awarded $20.2 million in damages.
📈 Amgen has delivered a 30.33% total shareholder return over the past year and a 68.20% return over three years.
💊 The company's pipeline includes high-margin assets like MariTide for obesity, Repatha for cardiovascular disease, and bispecific T-cell engagers for oncology.
📉 Legal risks persist as the verdict highlights ongoing patent litigation exposure in the biopharmaceutical sector.
⚠️ Revenue faces potential headwinds from tightening drug pricing regulations and competition from biosimilars.
💰 Amgen maintains its status as an established dividend payer with a solid balance sheet structure.
Bullish Signals
Trading at $344.72, ~2.1% below fair value of $352.23.
Achieved 30.33% return last year and 68.20% over three years.
Late-stage pipeline includes high-margin products like MariTide and Repatha.
Established dividend payer with a solid balance sheet.
Risk Factors
Guilty of patent infringement, ordered to pay $20.2M damages.
Exposed to tightening drug pricing pressures impacting growth and margins.
Bullish Signals
Amgen stock is trading at $344.72, which is approximately 2.1% below the calculated fair value of $352.23, suggesting a potential buying opportunity.
The company has achieved a strong 30.33% total shareholder return over the last year and a 68.20% return over three years, indicating sustained investor confidence.
Amgen's late-stage pipeline features high-margin, first-in-class products including MariTide for obesity and Repatha for cardiovascular disease that are poised to drive future growth.
The company is classified as an established dividend payer with a solid balance sheet, providing resilience against market volatility.
Risk Factors
Amgen was found guilty of willful patent infringement by Harbour BioMed's jury and ordered to pay $20.2 million in damages.
Amgen is exposed to potential tightening of drug pricing pressures which could impact future top-line growth and margins.
Amgen Inc. faces a significant legal setback after a Delaware federal jury ruled in June 2026 that the company willfully infringed on Harbour BioMed's Grosveld patent regarding antibody technology. The jury awarded Harbour BioMed exactly $20,203,704 in damages, with analysts noting that US law allows for potential enhancement of this award up to three times due to the finding of willful infringement.
This verdict has shifted analyst sentiment toward a reassessment of Amgen's intellectual property risk profile. While the majority of Wall Street analysts still maintain Buy or Overweight ratings, citing stable earnings from mature therapies and double-digit expected EPS, litigation over platform technologies is now explicitly flagged as a key risk factor affecting collaboration economics and long-term pipeline valuations.
Amgen remains a large-cap biotechnology leader in the S&P 500, generating revenue primarily from oncology, inflammation, and bone health drugs such as Neulasta, Prolia, and Repatha. As of June 2026, shares traded around $305 with a market capitalization of approximately $164 billion. Analyst consensus data suggests an average 12-month price target in the low $300 range, reflecting expectations for continued earnings contributions despite the legal headwind.
🏛️ Delaware jury found Amgen willfully infringed Harbour BioMed's patent in June 2026.
💰 Court awarded Harbour BioMed exactly $20,203,704 in damages for the infringement.
⚖️ Analysts warn US law permits enhancing damage award up to three times.
📉 Legal disputes over platform technologies flagged as key risk factor for Amgen stock.
💼 Majority of analysts still rate Amgen as Buy or Overweight despite verdict.
🏛️ A Delaware jury found Amgen willfully infringed Harbour BioMed's Grosveld antibody patent in June 2026.
💰 The court awarded Harbour BioMed exactly $20,203,704 in damages for the infringement.
⚖️ Analysts warn that US law permits enhancing the damage award up to three times due to willful infringement.
📉 Legal disputes over platform technologies are now flagged as a key risk factor for Amgen's stock.
💼 The majority of analysts still rate Amgen as Buy or Overweight despite the legal verdict.
📈 Analyst consensus shows double-digit expected earnings per share for the current fiscal year.
💊 Amgen generates revenue from mature therapies including Neulasta, Prolia, and Repatha.
📊 Shares traded at approximately $305 with a market cap of $164 billion as of June 2026.
🎯 The average 12-month price target among analysts is in the low $300 range.
Bullish Signals
Analysts maintain Buy or Overweight ratings despite legal losses.
Company maintains double-digit expected earnings per share this year.
Strong market position with stable revenue from mature drugs.
Shares traded at $305 showing sustained investor interest.
$164 billion market cap reflects S&P 500 leader status.
Risk Factors
Jury found willful infringement, exposing Amgen to up to three times initial award.
Analysts flag litigation and patent challenges as key stock risk factors.
Verdict forces reassessment of Amgen's IP risk profile and pipeline valuations.
Platform disputes could negatively impact collaboration economics with partners.
Bullish Signals
Majority of analysts maintain Buy or Overweight ratings on Amgen despite recent legal losses.
Company maintains double-digit expected earnings per share for the current fiscal year.
Amgen holds a strong market position with stable revenue from mature oncology and bone health drugs.
Shares traded at $305, indicating sustained investor interest in the biotech giant.
Market cap of $164 billion reflects its status as a large-cap S&P 500 leader.
Risk Factors
Jury found willful infringement of Harbour BioMed's patent, exposing Amgen to potential enhanced damages up to three times the initial award.
Analysts are explicitly flagging litigation and patent challenges as a key risk factor for the stock.
The legal verdict forces a reassessment of Amgen's intellectual property risk profile and long-term pipeline valuations.
Legal disputes over platform technologies could negatively impact collaboration economics with partners.
Amgen Inc. (AMGN) begins the week with muted news flow, as investors shift focus toward upcoming quarterly earnings expected in late July 2026 and key pipeline developments in obesity, oncology, and inflammation sectors.
Shares closed at $337.60 on June 18, 2026, trading slightly lower in extended hours, with the company maintaining its position as a major biotechnology player within the S&P 500 and Nasdaq-100 indices.
The company's revenue is primarily driven by innovative biologics including Repatha for cholesterol and Prolia for osteoporosis, alongside a growing portfolio of biosimilars marketed globally.
Market attention remains on late-stage drug programs such as AMG 133 (MariTide) and potential updates at medical conferences, which could influence long-term valuation despite the lack of immediate headlines.
📅 Earnings anticipated in late July 2026.
💰 Shares closed at $337.60 on June 18.
🏢 Market cap stands at approximately $181 billion.
💊 Revenue driven by Repatha, Prolia, and biosimilars.
🔬 Pipeline focuses on obesity, oncology, and inflammation.
📅 Amgen's next quarterly earnings are anticipated in late July 2026, though no official date has been released yet.
💰 Shares closed at $337.60 on June 18, 2026, with extended-hours trading showing a fractional decline to around $337.00.
🏢 The company holds a market capitalization of approximately $181 billion as of the latest reported close.
💊 Key revenue drivers include Repatha (cholesterol), Prolia (osteoporosis), and an expanding biosimilars portfolio.
🔬 Investors are monitoring pipeline catalysts in obesity, oncology, and inflammation for potential medium-term revenue shifts.
📊 Amgen is a constituent of both the S&P 500 and Nasdaq-100 indices.
🗣️ Management has identified obesity, cardiovascular disease, and oncology as primary growth pillars for future expansion.
Bullish Signals
Amgen market cap: $181 billion.
Blockbuster drugs: Repatha, Prolia.
Pipeline focus: Obesity, Oncology.
Risk Factors
Shares down in extended hours before earnings.
No official earnings date creates timing uncertainty.
Bullish Signals
Amgen maintains a substantial market capitalization of $181 billion, reflecting strong investor confidence in its biotechnology portfolio.
The company's diversified revenue stream includes established blockbuster drugs like Repatha and Prolia alongside a growing biosimilars business.
Pipeline focus on high-priority areas such as obesity (AMG 133) and oncology suggests potential for significant long-term growth catalysts.
Risk Factors
Shares traded fractionally lower in extended hours, suggesting cautious sentiment ahead of the upcoming earnings release.
No official earnings date has been posted yet, creating uncertainty regarding precise timing for investor expectations.
Amgen (AMGN) is the subject of recent market activity driven by a congressional portfolio shift and insider trading data. Representative David J. Taylor added Amgen shares to his holdings in early June, interpreted by observers as a preference for stable cash-flow generators amidst broader market rotations. While social media sentiment reflects measured optimism regarding the biotech sector's defensive qualities, the article notes that insiders have sold more than they have purchased over the last six months.
Financial performance and institutional ownership data provide further context to the stock's current standing. Amgen reported Q1 2026 revenues of $8.6 billion, representing a 5.76% increase year-over-year. Institutional investor activity has been mixed in the most recent quarter, with significant additions from Capital World Investors and Geode Capital Management offset by substantial reductions from Capital International Investors and JPMorgan Chase.
Analyst price targets for Amgen vary across major financial institutions, reflecting a range of valuations for the company's future prospects. Recent targets include $340 from Morgan Stanley and Guggenheim, $427 from Piper Sandler, and $400 from UBS. The median analyst target stands at $350.00, suggesting a consensus valuation that balances growth expectations with current market conditions.
📈 Rep. David J. Taylor added Amgen shares in early June.
💰 Q1 2026 revenues reached $8.6 billion, up 5.76%.
📉 Executives sold shares four times with zero purchases recently.
🏛️ Rep. Maria Elvira Salazar traded $100,000 in congressional activity.
📊 Institutional investors diverged: Capital World added 6.2M shares.
📈 Representative David J. Taylor added Amgen shares to his portfolio in early June, signaling a preference for stable cash-flow generators.
💰 Amgen reported Q1 2026 revenues of $8.6 billion, marking a 5.76% increase from the prior year.
📉 Insider trading data shows executives have sold shares four times in the past six months with zero purchases.
🏛️ Congressional trading activity includes Representative Maria Elvira Salazar making one purchase and one sale totaling $100,000.
📊 Institutional investors show divergent views, with Capital World Investors adding 6.2M shares while Capital International removed 11M shares.
🎯 Analyst price targets range from a low of $327 by Truist Securities to a high of $427 by Piper Sandler.
📉 The median analyst price target for Amgen is set at $350.00 across 14 analysts in the last six months.
Bullish Signals
Amgen revenue grew 5.76% in Q1 2026 to $8.6 billion.
Rep. Taylor initiated Amgen as a stable cash-flow generator.
Capital World Investors added 26.8%, increasing holdings by 6M shares.
Geode Capital Management added 1.1M shares, up 7.9%.
Piper Sandler analyst set $427 price target for growth.
Risk Factors
Insiders sold $21M in six months with no buys.
Capital International cut holdings by 60.8% (11M shares).
JPMorgan reduced stakes by 45.8% (nearly 2M shares).
Rockefeller Capital exited 71.9% of its position.
Pacer Advisors completely exited with all 1.6M shares.
Bullish Signals
Amgen achieved a 5.76% revenue growth in Q1 2026, reaching $8.6 billion.
Representative David J. Taylor initiated new positions in Amgen, viewing it as a stable cash-flow generator.
Capital World Investors increased their position by 26.8%, adding over 6 million shares.
Geode Capital Management added 1.1 million shares to its portfolio, increasing holdings by 7.9%.
Piper Sandler analyst David Amsellem set a high price target of $427, indicating strong growth potential.
Risk Factors
Amgen insiders have executed four sales totaling over $21 million in the past six months with no purchases.
Capital International Investors significantly reduced their position by removing 11 million shares (-60.8%).
JPMorgan Chase & Co. decreased its holdings by 45.8%, removing nearly 2 million shares.
Rockefeller Capital Management L.P. cut its position by 71.9%, exiting a significant portion of its stake.
Pacer Advisors, Inc. completely exited its position, removing all 1.6 million shares held.
A U.S. jury in Delaware has ruled that Amgen Inc. and its subsidiary Teneobio willfully infringed a key patent held by Harbour BioMed regarding antibody-discovery technology. The verdict, delivered following a trial that began June 8, 2026, found the defendants liable for patent infringement related to Harbour's proprietary transgenic rodent platform used to generate fully human antibodies.
The jury awarded Harbour BioMed $20.2 million in damages and unanimously upheld the validity of the 'Grosveld patent.' Because the infringement was determined to be willful, the court has the discretion to triple the damages to approximately $60.6 million if the judge agrees. This ruling represents a rare full victory for a smaller biotechnology firm against a major pharmaceutical giant in Delaware.
Harbour BioMed CEO Dr. Jingsong Wang described the decision as an 'epic victory' that reaffirms the company's status as the innovator behind transformative technology and validates its intellectual property portfolio. The case, originally filed in 2021, centers on foundational technologies critical for developing treatments for cancer and immune diseases, highlighting intensifying competition in the multibillion-dollar antibody therapeutics market.
Amgen stated it respects the jury's work but intends to pursue certain legal issues during post-trial proceedings. The verdict is expected to have wider ramifications for the global biotechnology sector by reinforcing legal protections for antibody-discovery platforms that underpin next-generation biologic drugs.
🏛️ Delaware jury found Amgen liable for willful patent infringement against Harbour BioMed.
💰 Jury awarded $20.2 million damages for antibody technology infringement.
Intensifying competition in multibillion-dollar antibody therapeutics market.
Bullish Signals
Harbour BioMed secured a decisive $20.2 million jury verdict against Amgen, validating its core intellectual property and technology platform.
The unanimous finding of patent validity strengthens Harbour's broader IP portfolio and deters future infringement attempts by large competitors.
The willful infringement ruling opens the possibility for damages to triple to roughly $60.6 million, significantly increasing potential financial recovery.
CEO Dr. Jingsong Wang highlighted that the victory reaffirms Harbour as the true innovator behind transformative antibody-discovery technology.
This rare win in Delaware sets a strong precedent for smaller biotechnology firms challenging major pharmaceutical companies over foundational patents.
Risk Factors
Amgen has indicated it will pursue certain legal issues during post-trial proceedings, suggesting the dispute may not be fully resolved immediately.
The potential for damages to triple to $60.6 million introduces uncertainty regarding the final financial outcome and timing of payments.
The case highlights intensifying competition over foundational technologies in the multibillion-dollar antibody therapeutics market.
Amgen announced that the European Commission has granted marketing authorization for IMDYLLTRA (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. This approval is based on results from the Phase 3 DeLLphi-304 trial, which demonstrated a significant survival benefit over standard of care chemotherapy in this setting. The trial showed that IMDYLLTRA reduced the risk of death by 40% and extended median overall survival by more than five months compared to chemotherapy (median OS: 13.6 vs. 8.3 months; hazard ratio, 0.60).
IMDYLLTRA is a first-in-class targeted immunotherapy engineered to bind to DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells. The drug was evaluated in the DeLLphi-304 study involving 509 patients randomized to receive either IMDYLLTRA or local standard of care chemotherapy (topotecan in most countries, with variations in the U.S., Canada, Australia, Singapore, South Korea, and Japan). Results were reviewed at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine.
The safety profile for IMDYLLTRA was consistent with its known profile, with cytokine release syndrome (CRS) being the most common adverse reaction (56.7%), followed by decreased appetite (36.4%) and pyrexia (31.9%). CRS primarily occurred after the first two doses, prompting recommendations for monitoring from the start of infusion for 6 to 8 hours on Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting. Other common adverse reactions included dysgeusia, constipation, anaemia, fatigue, nausea, asthenia, neutropenia, hyponatraemia, headache, and lymphopenia. Serious adverse reactions included CRS (19.7%) and pyrexia (4.7%).
Amgen's robust clinical development program includes the DeLLphi clinical trials, which evaluate IMDYLLTRA as a monotherapy and as part of combination regimens in both earlier stages of SCLC and earlier lines of treatment. The drug is indicated for the treatment of adult patients with ES-SCLC who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. Patients should be monitored closely for signs and symptoms of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment, with specific dosing schedules and monitoring protocols outlined in the Summary of Product Characteristics.
🏛️ European Commission approves tarlatamab for ES-SCLC after first-line chemo failure.
📉 Trial shows 40% lower death risk and 13.6 months median survival.
⚠️ Common side effects include CRS (56.7%) and neutropenia (16.9%).
🏛️ The European Commission has granted marketing authorization for Amgen's IMDYLLTRA® (tarlatamab) as a monotherapy for extensive-stage small cell lung cancer (ES-SCLC).
💊 This approval is specifically for adult patients requiring systemic therapy after disease progression on or after first-line platinum-based chemotherapy.
📉 The decision was based on the DeLLphi-304 Phase 3 trial, which showed a 40% reduction in the risk of death compared to standard-of-care chemotherapy.
⏳ Patients treated with IMDYLLTRA experienced a median overall survival of 13.6 months versus 8.3 months for those receiving chemotherapy alone.
🎯 IMDYLLTRA is the first and only T-cell engager therapy approved by the European Commission for the treatment of small cell lung cancer.
🔬 The drug works by binding to DLL3 on tumor cells and CD3 on T cells, activating T cells to kill cancer cells expressing the DLL3 protein.
⚠️ Cytokine release syndrome (CRS) was the most common adverse reaction, occurring in 56.7% of patients, primarily after the first two doses.
🧠 Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 4.7% of patients and can occur up to several weeks after administration.
🩸 Neutropenia was reported in 16.9% of patients, with grade 3 or 4 events occurring in 8.2% of the study population.
⚖️ The safety profile was consistent with known risks for this class of therapy, including serious infections and elevated liver enzymes.
🏥 Patients must be monitored from the start of infusion for 6 to 8 hours on Cycle 1 Day 1 and Day 8 in an appropriate healthcare setting.
💉 The recommended dosing schedule involves an initial dose of 1 mg on day 1 followed by 10 mg on days 8, 15, and every 2 weeks thereafter.
👩⚕️ Physicians experienced in cancer therapy must supervise the administration of IMDYLLTRA to manage severe reactions like CRS and neurologic toxicity.
🤝 Amgen's broader DeLLphi clinical program continues to evaluate tarlatamab in combination regimens and earlier stages of SCLC.
📰 Results from the pivotal DeLLphi-304 trial were previously presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine.
Bullish Signals
EC approved IMDYLLTRA® for ES-SCLC post-chemotherapy.
DeLLphi-304 trial cut death risk by 40%.
Median survival extended to 13.6 vs 8.3 months.
First T-cell engager therapy approved in Europe.
Targets DLL3 protein in up to 96% of patients.
Risk Factors
CRS occurred in 56.7% of patients; fatal cases reported.
Neurologic toxicity (ICANS) affected 65%; one fatal case.
Treatment discontinuation required for 0.6% due to CRS.
Serious infections including fatal cases reported with IMDYLLTRA.
Elevated liver enzymes in 39-43%; Grade 3/4 events rare.
Cytopenias common: neutrophils down 16%, platelets down 30%.
Requires specialized facility for monitoring severe reactions.
Patients must stay near facility 48 hours post-infusion.
Hypersensitivity reactions including bronchospasm reported.
Bullish Signals
The European Commission has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after first-line platinum-based chemotherapy.
The approval is based on the DeLLphi-304 Phase 3 trial, which demonstrated a significant survival benefit over standard of care chemotherapy, reducing the risk of death by 40% and extending median overall survival by more than five months (13.6 vs. 8.3 months).
IMDYLLTRA® is the first and only T-cell engager therapy approved to treat small cell lung cancer in Europe, marking a major milestone for patients with this aggressive disease.
The drug targets DLL3, a protein expressed on the surface of SCLC cells in up to 96% of patients, while being minimally expressed on healthy cells, offering a highly specific mechanism of action.
Amgen's robust clinical development program includes multiple ongoing Phase 3 studies (DeLLphi-303 through DeLLphi-313) evaluating IMDYLLTRA in earlier stages of SCLC and as part of combination regimens.
Results from the pivotal DeLLphi-304 study were reviewed at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine, validating the drug's efficacy in a global setting.
The safety profile was consistent with known characteristics, with manageable adverse reactions such as cytokine release syndrome (CRS) occurring primarily after the first two doses and resolving with appropriate monitoring and supportive care.
Risk Factors
Cytokine release syndrome (CRS) occurred in 56.7% of patients, with serious CRS events reported in 19.7%, and fatal CRS cases have been reported in the post-marketing setting.
Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred in 65% of patients, with life-threatening or fatal reactions reported, including one fatal ICANS case.
Treatment discontinuation due to CRS was required for 0.6% of patients, and treatment interruption or dose modification occurred in 2.1% of patients.
Serious infections, including life-threatening and fatal infections, have been reported in patients treated with IMDYLLTRA, with opportunistic infections occurring in 43% of the pooled safety population.
Hepatotoxicity was observed in the pooled safety population, with elevated ALT in 39% of patients and elevated AST in 43%, including Grade 3 or 4 events in 2.5% and 3.2% respectively.
Cytopenias are a significant risk, with decreased neutrophils occurring in 16% of patients (including 8.2% Grade 3 or 4) and decreased platelets in 30% (including 2.2% Grade 3 or 4).
The drug requires administration in an appropriate healthcare facility equipped to monitor and manage severe reactions like CRS and ICANS, limiting accessibility for patients.
Patients must remain within proximity of a healthcare facility for up to 48 hours following initial infusions, imposing logistical burdens on caregivers and patients.
Hypersensitivity reactions, including rare severe events such as bronchospasm, have been reported in patients treated with IMDYLLTRA.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
